88 related articles for article (PubMed ID: 1464120)
1. Distribution of pirarubicin in human blood.
Nagasawa K; Kitada N; Tsuji C; Ogawa M; Yokoyama T; Ohnishi N; Iwakawa S; Okumura K
Chem Pharm Bull (Tokyo); 1992 Oct; 40(10):2866-9. PubMed ID: 1464120
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of pirarubicin in plasma and cerebrospinal fluid.
Morikawa N; Takeyama M; Mori T; Hori S
Ann Pharmacother; 1998 Feb; 32(2):269. PubMed ID: 9496418
[No Abstract] [Full Text] [Related]
3. Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients.
Robert J; David M; Huet S; Chauvergne J
Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1289-94. PubMed ID: 3181250
[TBL] [Abstract][Full Text] [Related]
4. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.
Robert J; Monnier A; Poutignat N; Hérait P
Cancer Chemother Pharmacol; 1991; 29(1):75-9. PubMed ID: 1742853
[TBL] [Abstract][Full Text] [Related]
5. Transport mechanism of anthracycline derivatives in rat polymorphonuclear leukocytes: uptake of pirarubicin, daunorubicin and doxorubicin.
Nagasawa K; Nomiyama M; Ohnishi N; Yokoyama T; Iwakawa S; Okumura K
Biol Pharm Bull; 1994 Sep; 17(9):1305-8. PubMed ID: 7841960
[TBL] [Abstract][Full Text] [Related]
6. Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin.
Sugiyama T; Sadzuka Y; Nagasawa K; Ohnishi N; Yokoyama T; Sonobe T
Jpn J Cancer Res; 1999 Jul; 90(7):775-80. PubMed ID: 10470291
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of pirarubicin in pediatric patients.
Nagasawa K; Yokoyama T; Ohnishi N; Iwakawa S; Okumura K; Kosaka Y; Sano K; Murakami R; Nakamura H
J Pharmacobiodyn; 1991 Apr; 14(4):222-30. PubMed ID: 1941503
[TBL] [Abstract][Full Text] [Related]
8. Transport mechanism of anthracycline derivatives in rat polymorphonuclear leukocytes: uptake and efflux of pirarubicin.
Nagasawa K; Nomiyama M; Ohnishi N; Yokoyama T; Iwakawa S; Okumura K
Biol Pharm Bull; 1994 May; 17(5):696-700. PubMed ID: 7920436
[TBL] [Abstract][Full Text] [Related]
9. Thermal enhancement of pirarubicin (THP-adriamycin) by mild hyperthermia in vitro.
Takahashi T; Mitsuhashi N; Sakurai H; Murata O; Kitamoto Y; Matsumoto H; Higuchi K; Niibe H
Int J Hyperthermia; 1997; 13(3):317-24. PubMed ID: 9222814
[TBL] [Abstract][Full Text] [Related]
10. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells.
Nagasawa K; Natazuka T; Chihara K; Kitazawa F; Tsumura A; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Cancer Chemother Pharmacol; 1996; 37(4):297-304. PubMed ID: 8548874
[TBL] [Abstract][Full Text] [Related]
11. A limited sampling strategy for the study of pirarubicin pharmacokinetics in humans.
Marchiset-Leca D; Leca FR; Galeani A; Noble A; Iliadis A
Cancer Chemother Pharmacol; 1995; 36(3):233-8. PubMed ID: 7781144
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics of new anthracyclines].
Robert J
Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacological study of intra-arterial hepatic administration of pirarubicin in patients with advanced hepatic metastases.
Munck JN; Rougier P; Chabot GG; Ramirez LH; Bognel C; Lumbroso J; Herait P; Elias D; Lasser P; Gouyette A
Eur J Cancer; 1994; 30A(3):289-94. PubMed ID: 8204346
[TBL] [Abstract][Full Text] [Related]
14. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
[TBL] [Abstract][Full Text] [Related]
15. Transport mechanism of anthracycline derivatives in rat polymorphonuclear leukocytes: effect of sodium fluoride on pirarubicin uptake.
Nagasawa K; Tsumura A; Kitazawa F; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1995 Feb; 18(2):368-71. PubMed ID: 7742815
[TBL] [Abstract][Full Text] [Related]
16. [Chemical stability of pirarubicin in its use for continuous infusion].
Leca F; Marchiset-Leca D; Nobili-Pieri N; Galeani A; Durieux-Joubert A
Bull Cancer; 1996 Nov; 83(11):923-8. PubMed ID: 9033602
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology and antitumour effects of intraportal pirarubicin on experimental liver metastases.
Ramirez LH; Munck JN; Bognel C; Zhao Z; Ardouin P; Poupon MF; Gouyette A; Rougier P
Br J Cancer; 1993 Aug; 68(2):277-81. PubMed ID: 8347482
[TBL] [Abstract][Full Text] [Related]
18. Prospects for pirarubicin.
Miller AA; Salewski E
Med Pediatr Oncol; 1994; 22(4):261-8. PubMed ID: 8107658
[No Abstract] [Full Text] [Related]
19. Intrapleural pirarubicin (4'-O-tetrahydropyranyladriamycin) for treatment of malignant pleural effusion.
Gotoh T; Tanaka Y; Fujita Y; Hiramori N; Fujii T; Arimoto T; Iwasaki Y; Fukabori T; Nakamura T; Ono N; Nakagawa M
Jpn J Clin Oncol; 1996 Oct; 26(5):328-34. PubMed ID: 8895673
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
